Abstract: The present application relates to creamer comprising vegetable lipids, casein, maltose, phosphates, and allulose.

Abstract: A lidar sensor device according to an embodiment includes a data generation unit that generates light identification data, an optical modulation unit that generates a plurality of modulated signals for the optical identification data by performing orthogonal frequency division multiplexing (OFDM) modulation on the optical identification data and generates a plurality of laser signals respectively corresponding to the plurality of modulated signals and having different frequencies, and a transmission unit that simultaneously transmits the plurality of laser signals to different measurement points according to the frequencies, respectively.

Abstract: A method for screening a functional material according to the present invention comprises steps of: treating a linker material-coated substrate with a capture protein; treating the capture protein-treated substrate with a functional material candidate; treating the functional material candidate-treated substrate with biotin-conjugated IgE; and treating the biotin-bound IgE-treated substrate with fluorescently labeled streptavidin.

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: Disclosed are a drug evaluation method and apparatus. The drug evaluation method includes acquiring cell images in response to a drug to be evaluated, loading an image processing-based learning model trained so as to predict molar concentrations, outputting molar concentrations of cells corresponding to the cell images by applying the learning model to the acquired cell images, and calculating a drug evaluation value used to evaluate effects of the drug on the cells based on the molar concentrations of the cells corresponding to the cell images output through the learning model.

Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.

Abstract: The present invention relates to a composition for the diagnosis of a degenerative brain disease, comprising hpmA, which is a substance derived from Proteus, Shigella, Klebsiella pneumoniae, or Citrobacter, preferably a Proteus mirabilis strain, from a biological sample of a subject. In addition, the present invention relates to a method for providing information for the diagnosis of a degenerative brain disease such as Parkinson's disease, brain neuritis (neuroinflammation), or Alzheimer's disease, by measuring the amount of hpmA.

Abstract: A new and distinct cultivar of Stokesia plant named ‘STAM01’ is disclosed, characterized by floriferous plants with strong stems and dense foliage. Flowers are large. The new variety is a Stokesia, suitable for outdoor garden and container uses.

Abstract: An optical path control member according to an embodiment comprises: a first substrate; a first electrode provided on the upper portion of the first substrate; a second substrate provided on the first substrate; a second electrode provided on the lower portion of the second substrate; and an optical conversion unit provided between the first electrode and the second electrode, wherein the optical conversion unit comprises partition wall parts and accommodation parts which are alternately arranged. The accommodation parts have a light transmission rate that varies according to the application of a voltage, and the accommodation parts comprise a plurality of unit accommodation cells spaced apart from each other, and comprises a dispersion and light-absorbing particles which are dispersed in the dispersion.

Abstract: A quantum dot including a core that includes a first semiconductor nanocrystal including zinc and selenium, and optionally sulfur and/or tellurium, and a shell that includes a second semiconductor nanocrystal including zinc, and at least one of sulfur or selenium is disclosed. The quantum dot has an average particle diameter of greater than or equal to about 13 nm, an emission peak wavelength in a range of about 440 nm to about 470 nm, and a full width at half maximum (FWHM) of an emission wavelength of less than about 25 nm. A method for preparing the quantum dot, a quantum dot-polymer composite including the quantum dot, and an electronic device including the quantum dot is also disclosed.

Abstract: An optical path control member according to an embodiment comprises: a first substrate; a first electrode arranged on the upper surface of the first substrate; a second substrate arranged on top of the first substrate; a second electrode arranged on the lower surface of the second substrate; and an optical conversion unit which is arranged between the first electrode and the second electrode and which defines a first direction and a second direction, wherein the optical conversion unit comprises a partition part and an accommodation part that are alternately arranged in the first direction, the accommodation part includes a plurality of cells arranged to be spaced in the second direction, at least one of the cells includes a first inner side surface and a second inner side surface that are connected to each other, and the first inner side surface and/or the second inner side surface extends in a direction other than the first and second directions.

Abstract: The present invention relates to an allulose storage package for increasing storage stability of allulose syrup and a method for increasing the storage stability of allulose.

Abstract: The present invention relates to a dextrin with improved turbidity, and a method for producing same.

Abstract: A quantum dot light-emitting device including first electrode and a second electrode, a quantum dot layer between the first electrode and the second electrode, a first electron transport layer and a second electron layer disposed between the quantum dot layer and the second electrode. The second electron transport layer is disposed between the quantum dot layer and the first electron transport layer, wherein each of the first electron transport layer and the second electron transport layer includes an inorganic material. A lowest unoccupied molecular orbital energy level of the second electron transport layer is shallower than a lowest unoccupied molecular orbital energy level of the first electron transport layer, and a lowest unoccupied molecular orbital energy level of the quantum dot layer is shallower than a lowest unoccupied molecular orbital energy level of the second electron transport layer. An electronic device including the quantum dot light-emitting device.

Abstract: A novel quinazoline compound having SOS1 inhibitory activity and uses of the quinazoline compound are disclosed. More particularly, the present invention relates to a novel quinazoline derivative compound having inhibitory activity on SOS1 binding to RAS family proteins and/or RAC1, to pharmacologically acceptable salts thereof, and to pharmaceutical compositions containing the quinazoline compound. The novel quinazoline compound has the following chemical formula 1: wherein all the variables have meaning as defined in the specification.

Abstract: An optical path control member according to an embodiment comprises: a first substrate; a first electrode disposed on the first substrate; a second substrate disposed on the first substrate; a second electrode disposed under the second substrate; and a photoconversion unit disposed between the first electrode and the second electrode, wherein the second substrate includes at least one hole penetrating the second substrate, and an electrode connection part connected to a side surface of the second electrode is disposed inside the hole.

Abstract: An arylamine-fluorene alternating copolymer having a structural unit (A) is represented by Chemical Formula (1): wherein Chemical Formula (1) is the same as described in the detailed description.

Abstract: A light path control member according to an embodiment comprises: a first substrate by which a first direction and a second direction are defined; a first electrode disposed on the first substrate; a second substrate disposed on the first substrate; a second electrode disposed under the second substrate; and a light conversion unit disposed between the first electrode and the second electrode, wherein the light conversion unit comprises: a plurality of partitions; a plurality of accommodation units; and a base, wherein the accommodation units extend in the second direction, the first electrode includes a plurality of first pattern electrodes extending in the second direction and spaced apart from each other, and the first pattern electrodes overlap the accommodation units.

Abstract: The present invention relates to a composition for an organic optoelectronic device, and an organic optoelectronic device and display device comprising same, the composition including a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2, or a first compound represented by Chemical Formula 1 and a third compound represented by a combination of Chemical Formula 3 and Chemical Formula 4. The details of Chemical Formula 1 to Chemical Formula 4 are as defined in the specification.

Abstract: A light path control member according to an embodiment comprises: a first substrate; a first electrode disposed on the first substrate; a second substrate disposed on the first substrate; a second electrode disposed under the second substrate; a light conversion unit disposed between the first electrode and the second electrode; an adhesive layer between the second electrode and the light conversion unit; and a buffer layer between the first electrode and the light conversion unit. The light conversion unit includes a plurality of partition wall portions, a plurality of accommodation portions, and a base portion. The accommodation portions have a light conversion material disposed therein, and include at least two sealing regions formed on at least one of the first substrate or the second substrate.